01 February 2023>: Lab/In Vitro Research
Neutrophil-to-Platelet Ratio in Patients with Ulcerative Colitis Treated with Infliximab or Vedolizumab: A Retrospective, Single-Center Study in Poland
Marcin Warpechowski 1CD* , Jędrzej Warpechowski 2AEF , Anita Pieńkowska 2BEF , Szymon Sagała 2BEF , Robert Milewski 1CDEDOI: 10.12659/MSM.938827
Med Sci Monit 2023; 29:e938827
Figure 1 Box-plot comparison between average value of neutrophil-to-platelet ratio during the induction phase between patients with sustained response and loss of response to infliximab or vedolizumab. Small squares represent the median value. The figure was created using Statistica version 13 (TIBCO Software, Inc.).